182 related articles for article (PubMed ID: 38670729)
1. Imaging in Rheumatic Immune-related Adverse Events.
Zhang J; Ni R; Oke I; Calabrese C; Strouse J; Weinmann S; Ladouceur A
Rheum Dis Clin North Am; 2024 May; 50(2):313-323. PubMed ID: 38670729
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
[TBL] [Abstract][Full Text] [Related]
3. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
[TBL] [Abstract][Full Text] [Related]
5. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
7. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
9. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
[TBL] [Abstract][Full Text] [Related]
10. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
[TBL] [Abstract][Full Text] [Related]
11. Patient Voices in Rheumatic Immune-related Adverse Events.
Corps KN; Terry O; Lopez-Olivo MA
Rheum Dis Clin North Am; 2024 May; 50(2):241-254. PubMed ID: 38670723
[TBL] [Abstract][Full Text] [Related]
12. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
13. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Abdel-Wahab N; Suarez-Almazor ME
Expert Rev Clin Immunol; 2024 Mar; ():1-21. PubMed ID: 38400840
[TBL] [Abstract][Full Text] [Related]
14. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Shen P; Deng X; Hu Z; Chen Z; Huang Y; Wang K; Qin K; Huang Y; Ba X; Yan J; Han L; Tu S
Front Med (Lausanne); 2021; 8():762247. PubMed ID: 34805229
[TBL] [Abstract][Full Text] [Related]
15. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
16. Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe M; Bermas BL
Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
[TBL] [Abstract][Full Text] [Related]
17. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Lee KA; Kim HR; Yoon SY
Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
19. De novo Connective Tissue Disorders as Immune-related Adverse Events.
Cho LK; Jamal S
Rheum Dis Clin North Am; 2024 May; 50(2):301-312. PubMed ID: 38670728
[TBL] [Abstract][Full Text] [Related]
20. Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
